Press Releases

 
Press Releases
  Date Title and Summary View
Jun 10, 2016
CRANBURY, N.J., June 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced the election and appointment of Craig A. Wheeler to its Board of Directors, effective immediately. In addition, Amicus announced that John F. Crowley, Margaret G. McGlynn, Micha...
PDF
Jun 1, 2016
CRANBURY, N.J., June 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the Goldman Sachs 37th Annual Global Heal...
PDF
May 31, 2016
Launch has Begun in Germany Broad Label for All Fabry Patients with an Amenable Genetic Mutation First Precision Medicine Approved for Fabry Disease CRANBURY, N.J., May 31, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that the European Com...
PDF
May 5, 2016
CRANBURY, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Wed...
PDF
May 3, 2016
Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations  Actively Enrolling Patients Across Multiple Sites in Clinical Study to Investigate Novel Enzyme Replacement Therapy for Pompe Disease Company to Remain Within Original Full-Year 2016 Net Cash Spend Guidance of $135M-$155M CRANBURY, N.J...
PDF
Apr 26, 2016
CRANBURY, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 3, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2016. The call will be ...
PDF
Apr 1, 2016
Broad Label for All Fabry Patients with an Amenable Genetic Mutation Conference Call Today at 12:30 pm ET CRANBURY, N.J., April 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that the European Committee for Medicinal Products for Human Us...
PDF
Mar 22, 2016
CRANBURY, N.J., March 22, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, has initiated a reimbursed expanded access program (EAP) to provide Fabry patients who have amenable mutations with access to migalastat. The EAP will be implemented in certain t...
PDF
Mar 2, 2016
CRANBURY, N.J., March 02, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Bradley L. Campbell, President and Chief Operating Officer, will present a corporate overview at the Cowen and Company 36th Annual Health Care Conference in ...
PDF
Mar 1, 2016
New Phase 3 Data for Migalastat for Fabry Disease Demonstrate Persistence of Positive Renal and Cardiac Effects and Substrate Reduction in Important Kidney Cell Type (Podocytes) Preclinical Proof-of-Concept Data Informed Ongoing Clinical Study of Novel Pompe Treatment Paradigm SAN DIEGO and CRANBURY, N.J., March 01, 2016 (GLOBE NEWSWIRE) --...
PDF
Page:
1
... NextLast